Czechia· CZ-0270678

LANREOTID SUN

A lanreotide product containing lanreotide acetate, registered in Czechia by Sun Pharmaceutical Industries Europe B.V., Hoofddorp. The same ATC class is registered in 17 of our 19 countries.

ATC H01CB03

Checked against SÚKL (Czech Republic) on

Informational only — not a medical device.

SOURCE REGISTER · CZSÚKL (Czech Republic)normalisedLANREOTID SUNATCH01CB03REGISTER NO.CZ-0270678PACKS LISTED0CHECKEDSeptember 28, 2026

Where it is registered

Lanreotide is registered in 17 of 19 countries.

Countries holding a registration under ATC H01CB03 (lanreotide), each read from that country’s own register.

  • This record: Czechia, from SÚKL (Czech Republic)
  • 10 of them publish a price we can compare per daily dose

Lanreotide · ATC H01CB03

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of lanreotide costs, country by country.

Normalised to the WHO defined daily dose (3 mg), so markets compare like for like.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Lanreotide · price per daily dose (3 mg)

USD · FX 28 Sept 2026

  • FR France$53.80
  • CH Switzerland$44.46
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

SÚKL (Czech Republic)
Active substance
LANREOTIDE ACETATE
Manufacturer
Sun Pharmaceutical Industries Europe B.V., Hoofddorp
Country
Czechia (CZ)
ATC code
H01CB03
ATC class
Lanreotide
Defined daily dose
3 mg, P
Reimbursed
Not published by this register
Source register
SÚKL (Czech Republic)
Last checked
September 28, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

157 interactions on record for lanreotide.

Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Lanreotide · interactions on record

157 records

  • 2 severe
  • 151 moderate
  • 4 minor

Most severe, free to view

  • LonafarnibA16AX20severe
  • PexidartinibL01EX15severe
  • LiraglutidA08AX02moderate
  • SemaglutidA08AX03moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Lanreotide in 4 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All lanreotide products

Authorised across Europe · EMA

The same active substance is authorised in 5 EEA countries. Names it is sold under:

  • France · Myrelez L.P.
  • United Kingdom (Northern Ireland) · Lanreotide Sun
  • Hungary · Mytolac
  • Netherlands · Mytolac
  • Poland · Lanreotide Ranbaxy

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/d03d763b-018d-4863-84f5-c18b492c2d09
GET /v1/drugs/d03d763b-018d-4863-84f5-c18b492c2d09?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "INJ SOL ISP",
  "source": "sukl",
  "strength": "90MG",
  "pack_size": "1X0,5ML+1FJ",
  "substance": "LANREOTIDE ACETATE",
  "cz_kod_sukl": "0270678",
  "product_type": "CH",
  "substance_codes": "14862",
  "registration_state": "R",
  "registration_number": "56/462/22-C"
}

See everything about lanreotide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.